Considerations for the Use of Temporary Surge Sites for Managing Seasonal Patient Surge
U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response. 02/12/2018 This 18-page document from TRACIE (Technical Resources, Assistance Center, and Information Exchange) describes the major considerations healthcare facility emergency planners must consider when determining patient surge management solutions for longer-duration events, such as weeks to months of managing seasonal illness surge. During the severe 2017-2018 influenza season, coupled with increases in other upper respiratory infections, many hospitals have surpassed routine surge management measures and have initiated temporary surge solutions. (PDF)
After a two-year hiatus, the nasal flu vaccine is set to return to doctors’ offices next year. The Advisory Committee on Immunization Practices (ACIP) voted 12 to 2 on Wednesday to return the nasal spray to the CDC’s list of recommended vaccines for the 2018-2019 flu season. Pending final approval from the CDC director, the vote would greenlight the spray for widespread use and compel insurance companies to cover it. The committee stopped short of explicitly recommending the nasal spray, however, and will instead let providers and patients decide if they’ll use it instead of traditional flu shots. There ...
Flu levels remain high across all four UK nations, with consultation rates above baseline thresholds and a rise in cases in Scotland over the past week, latest official data show.
A. H. Salaheldin et al.
On 14 February 2018, the National Health and Family Planning Commission (NHFPC) of China notified the World Health Organization (WHO) of one case of human infection with avian influenza A(H7N4) virus. This is the first human case of avian influenza A(H7N4) infection to be reported worldwide.
Flu vaccinations may become painless again. A US Centers for Disease Control and Prevention advisory committee voted Wednesday to recommend, once again, that FluMist, the nasal spray version of the influenza vaccine, be used during the 2018-19 season.
ConclusionsThe results indicate that Flu A detection by TD-01 is particularly suitable for on-site testing and has the potential for application in point-of-care testing.
Influenza is associated with rapid evolution due to lack of RNA polymerase proofreading, immunogenic selection, and frequent rearrangement of gene segments. Evolutionary changes affecting the performance of diagnostic testing have long been recognized. Hence, it is not surprising that such challenges apply to nucleic acid amplification tests, even though they are designed to target highly conserved regions. Initially, case reports involved single isolates of A(H1N1)pdm09. Over the past 4 years, subtype H3N2 viruses evolved to viral clades with mutations in the WHO-recommended target region, such that almost all isolates wo...
Rapid identification of respiratory pathogens, such as influenza virus A (FluA), influenza virus B (FluB), and respiratory syncytial virus (RSV), reduces unnecessary antimicrobial use and enhances infection control practice. We performed a comparative evaluation of three molecular methods: (i) the Aries Flu A/B &RSV, (ii) the Xpert Xpress Flu/RSV, and (iii) the Cobas Flu A/B &RSV assays. The clinical performances of the three methods were evaluated using 200 remnant nasopharyngeal swab (NPS) specimens against a combined reference standard. The limits of detection (LODs) were determined using FluA, FluB, and RSV con...
Na Zhao, Supen Wang, Hongyi Li, Shelan Liu, Meng Li, Jing Luo, Wen Su, Hongxuan He